BioSpace News Archive

Business

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2023 and provided an update on recent corporate highlights.

May 8, 2023
·
7 min read
Business

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended March 31, 2023 and provided a business update.

May 8, 2023
·
10 min read
Biotech Beach

Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, announced that it has raised $40 million in new financing.

May 8, 2023
·
2 min read
Business

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts.

May 8, 2023
·
10 min read
Biotech Bay

Dynavax to Present at the JMP Securities Life Sciences Conference - May 08, 2023

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, at 1:00 p.m. E.T.

May 8, 2023
·
1 min read
Business

Shockwave Medical Reports First Quarter 2023 Financial Results

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

May 8, 2023
·
8 min read
Business

Treace Medical Concepts Reports First Quarter 2023 Financial Results

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023.

May 8, 2023
·
14 min read
Biotech Bay

4D Molecular Therapeutics to Participate in Upcoming May 2023 Investor Conferences

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced it will participate in the following upcoming investor conferences.

May 8, 2023
·
2 min read
Business

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the first quarter of 2023 and recent clinical program updates.

May 8, 2023
·
9 min read
Biotech Bay

Codexis Announces New Employment Inducement Grants - May 08, 2023

Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors.

May 8, 2023
·
1 min read